Tumors use many mechanisms to evade the immune system, including manipulating various cellular pathways, such as immune checkpoints, to evade cell death. The PD-L1/PD-1 immune checkpoint pathway is one such mechanism and, in recent years, has become a promising target for immuno-oncology drug development. 1 Tumor cells' expression of PD-L1 leads to the inhibition of immune responses by creating a locally immunosuppressive tumor microenvironment, allowing for evasion of immune checkpoints and the inactivation of cytotoxic T cells, 2 resulting in reduction of autoimmunity, promotion of self-tolerance, and, ultimately, a poor prognosis for the patient. [3] [4] [5] PD-L1/PD-1 therapy has recently been shown to be effective in treating patients with non-small cell lung cancer (NSCLC). [6] [7] [8] However, in clinical trials using PD-L1 mAb to treat NSCLC, although PD-L1-"positive" tumors (as assessed by immunohistochemistry [IHC] using the Dako IHC 28-8 pharmDx assay [Agilent, Santa Clara, CA]) did show superior benefit from anti-PD-L1 mAb treatment compared with PD-L1-negative patients, a significant number of PD-L1-negative patients also showed a clinical benefit from treatment. 9 Clearly, there exists a significant challenge in segregating potential responders from nonresponders prior to treatment-the "positive" cutoffs using standard companion IHC tests for PD-L1 expression exclude a significant number of responders, in the range of approximately 10% to 20%. 9 This may be in due in part to the subjective interpretation of IHC results, as well as antibody and assay variability. 10 In addition, it has been shown that PD-L1 is expressed not only by tumor cells but also by myeloid cells located in the tumor microenvironment. 11 Thus, it has become clear that assessment of PD-L1 expression on tumor cells alone does not provide a complete picture of the tumor's profile, lacking additional information needed to understand the role of immune cell infiltrates. Immunophenotyping subpopulations of immune cells requires multiplexing of cell surface markers, a technical hurdle that IHC has yet to overcome. 12 Immune cell numbers and function are also key determinants of response to immunotherapy [13] [14] [15] ; thus, an assay that can not only nonsubjectively quantify PD-L1 expression but also quantify and determine immune cells' function within a single assay would be a major advancement in patient treatment and management given the complexity of the immune response against solid tumors.
Tumors lie within a tumor microenvironment that includes the tumor, immune cells, and stroma, which all interact to determine the fate of that particular cancer. 16 More than ever, precision medicine is needed to assimilate and assess all of the information concerning a tumor and its microenvironment that can contribute significantly to therapeutic decisions and prognosis. The goal of diagnostics should be to glean the most information from a tumor using the samples at hand. Herein, we present a novel clinical technology that provides information regarding multiple factors that contribute to prognosis and treatment, including quantification of tumor-infiltrating lymphocytes (TILs), quantification of PD-L1 expression, and quantification of tumor aneuploidy (a measure of cell cycle and genomic instability). Furthermore, we will demonstrate that tumors have a varying number of tumor cell clones and that PD-L1 expression varies depending on the DNA content of cells.
Thus, the goal of the current study was to validate the prognostic and therapeutic markers mentioned above both simultaneously and in a single sample prepared from primary NSCLC tumors using the OncoTect iO Lung Assay (IncellDx, San Carlos, CA) by comparing the results with the currently used standard immmunohistochemical quantification of PD-L1.
Materials and Methods

Samples
Fresh tissues were obtained from 19 NSCLC cases following informed consent and institutional review board approval. Date of collection, age, sex, ethnicity, diagnosis, primary tumor size, and American Joint Committee on Cancer classification were recorded. Tissues were excised and then stored in RPMI 1640 medium at 2°C to 8°C prior to overnight shipment to IncellDx (Menlo Park, CA) on cold packs.
Tissue Dissociation Using IncellPREP
Tumor biopsy specimens of at least 100 mg were placed in RPMI for transport after which 4-mm punches were taken from each tissue, of the entire tissue, and placed into Eppendorf tubes containing 800 μL Dulbecco's phosphate-buffered saline (DPBS). The entire tissue was used to generate the most representative single-cell pool of cells to account for tumor heterogeneity across the tissue. IncellPREP (IncellDx) tissue homogenizers were inserted into each tube and set to run until supernatant appeared cloudy (<7.5 minutes). Cells were pelleted by centrifugation at 600g and fixed and permeabilized in 1 mL IncellMax per 1 million live cells by trypan blue staining.
OncoTect iO Assay
Aliquots of 250,000 viable cells were tested at TriCore Reference Laboratories (Albuquerque, NM) with the OncoTect iO Lung Assay, which contains antibodies directed against PD-L1 (28-8), CD45, CD3, and CD8, and a cell cycle dye. Following fixation for 1 hour in IncellMax, 250 µL of sample equivalent to 250,000 cells was aliquoted to 12 × 75-mm tubes and subsequently washed with 1 mL DPBS + 2% bovine serum albumin (BSA). Samples were stained with the OncoTect iO Lung Assay incorporating conjugated anti-human antibodies in DPBS + 2% BSA, and then incubated for 30 minutes at room temperature in the dark. Next, 1 mL DPBS + 2% BSA was added to each tube and incubated at room temperature for 5 minutes, prior to centrifugation at 600g for 5 minutes. Supernatant was aspirated, and a wash with DPBS + 2% BSA was repeated once. Following this wash, 100 µL of cell cycle dye at 1 µg/mL was added to each sample and incubated at room temperature for 30 minutes in the dark.
Flow Cytometry
Cells were first analyzed on a CytoFlex Cytometer (Beckman Coulter) using a PB450-Area by PB450-Height density plot to set a gate on nucleated single cells by the cell cycle dye staining. That gate was then applied to a CD45-FITC by side scatterplot to separate CD45+ immune cells from CD45-cells (epithelial/tumor cells). Immune cells were further separated into CD3+ and CD3+/CD8+ populations by a CD8-PC5 by CD3-PE scatterplot. A gate was established around the CD8+/CD3+ cells (cytotoxic T cells). In addition, a PB450-Lin by count plot was used to gate on the CD45-diploid population. Once those populations were determined, each was analyzed for PD-L1 expression by forward scatter. A putative gate was established based on low/normal PD-L1 expression and was validated by this 19-sample data set. PD-L1 expression above the normal cutoff was recorded for the CD45-population. Similarly, the presence of aneuploid cells was determined by calculating the ratio of cell cycle signal in the diploid gate for the CD45-and lymphocyte populations. A ratio of more than 1.05 (DNA index) is indicative of aneuploidy. When a ratio of more than 1.05 was determined, PD-L1 expression on the aneuploid CD45-cells was recorded.
Immunohistochemistry
Concordance to IHC was tested by obtaining matched/split formalin-fixed, paraffin-embedded (FFPE) sections from the tissue biopsy specimens. FFPE blocks were sectioned at a 5-μm thickness. Slides were deparaffinized in a series of xylenes and progressively diluted alcohols to water. After rinsing with deionized water, the slides were treated with citrate-based antigen retrieval solution that was preheated to 65°C. Slides were incubated in the preheated citrate buffer and heated for 20 minutes at 99°C and cooled down for 20 minutes before commencing IHC staining on the Dako autostainer. Endogenous peroxidase was quenched with peroxidase quencher solution, followed by protein blocking and rabbit anti-PD-L1 antibody (28-8 clone) incubation for 1 hour at room temperature. Relevant nonspecific isotype control was used as negative control. After rinsing the primary antibodies, the slides were incubated with biotin-conjugated secondary antibody and horseradish peroxidase (HRP) enzymeconjugated streptavidin, followed by incubation with diaminobenzidine to visualize the signal. Upon completion of the IHC staining, the slides were dehydrated in a series of alcohols and xylenes followed by cover-slipping for microscopic evaluation.
Statistical Analysis
Comparison between groups was performed using the Student t test or the Mann-Whitney rank sum test. Statistical significance was determined with a P ≤ .05 value.
Results
NSCLC TIL Quantification
To determine the composition of the immune cell infiltrates in the 19 study samples, the OncoTect iO Lung Assay generated immune subset information on all samples ❚Table 1❚.
Comparing immune cell subsets in the tumor samples with normal lung tissue samples, there was a statistically significant decrease in helper T cells (CD3+/CD8-) (P = .05), while cytotoxic T cells (CD3+/CD8+) in the tumor samples were only slightly and nonsignificantly elevated in tumor relative to normal lung samples ❚Figure 1A❚. Interestingly, the percentage of antigen-presenting cells (APCs) (CD45+, hi side scatter) was decreased in the tumor tissue samples relative to the normal lung tissue. This finding was also statistically significant (P = .02).
To determine if the TILs were functioning, we determined proliferation by quantifying the post-G 0 -G 1 percent as previously described. 17 As demonstrated in ❚Figure 1B❚, proliferation in both the CD8+ TILs and the CD4+ TILs was increased relative to normal lung tissue, although the increase was statistically significant only in the CD4+ T-helper population (P = .02).
Single-Cell PD-L1 Quantification (OncoTect iO) by Flow Cytometry Compared With Immunohistochemical Determination of PD-L1 Expression
To determine the correlation between single-cell PD-L1 quantification done nonsubjectively using flow cytometry and the clinical standard immunohistochemistry, we analyzed matched/split samples with one tissue sample submitted for FFPE slides and another contiguous sample processed through an in vitro diagnostic, enzyme-free, single-cell preparation device as previously described. 17 As shown in ❚Figure 2❚, multiparameter flow cytometry was performed, and single nucleated cells were gated using PB450-Area vs PB450-Height dot plot analysis. Single nucleated cells were electronically separated into immune (CD45+, CD3+, CD4+, CD8+) populations and CD45-, diploid, and aneuploid tumor cell populations. PD-L1 was quantified in the tumor cell and aneuploid tumor cell populations. PD-L1 quantification on the tumor cell population was compared with IHC quantification as previously described. 17 Comparison of the OncoTect iO Lung Assay with the Dako PD-L1 IHC 28-8 PharmDx Kit revealed an overall concordance of 95% ❚Table 2❚, with detection of one positive result by the OncoTect iO Lung Assay that was missed by IHC ( Table 1 ). The negative percent agreement was 97% and the positive percent agreement was 89%.
NSCLC Tumor Cell Cycle/Aneuploid Analysis
To determine if differences in PD-L1 expression exist relative to DNA content, we quantified PD-L1 expression as a function of DNA content ❚Figure 3❚. As shown in Figure 3 , DNA content as measured by fluorescence intensity typically appears as one chromosome equivalent (1C) with a small population of cells just prior to cell division appearing as twice (2C) the fluorescence intensity of diploid cells (1C). Tumor cells that are aneuploid have a DNA content that does not fall into the 1C or 2C fluorescence equivalents. PD-L1 expression was found to vary in cells in different phases of the cell cycle, depending on the patient. In particular, the expression of PD-L1 was increased in the aneuploid populations relative to the diploid populations (Table 1, Figure 3) .
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❚Figure 1❚ A, Immune profiling of immune cell in IncellPREP-prepared single-cell suspensions from non-small cell lung cancer (NSCLC) samples. CD8+ cytotoxic T lymphocyte (CTL) percentages were similar in NSCLC samples and normal lung controls, but there was a statistically significant decrease in CD4+ T-helper cells (*P = .05) and macrophages (**P = .02) in NSCLC samples compared with normal lung controls. B, Proliferation of T-cell subsets in NSCLC compared with normal lung samples. Proliferation is increased in both CD8+ CTL and CD4+ helper T cells relative to normal samples, with the increase being statistically significant in the CD4 helper T-cell subset (P = .02).
Heterogeneity in NSCLC, both within tumor cells and in the tumor microenvironment, leads to challenges in tailoring effective patient treatment strategies. Most molecular-based precision medicine diagnostics extract nucleic acids from these heterogeneous tumors and may lose the context from which markers are expressed. Diagnostic approaches such as the one presented here can address issues with tumor heterogeneity and the microenvironment by characterizing both the tumor and the tumor microenvironment using a cell-based, multiparameter assay platform. Herein, we have presented a novel clinical assay that contributes actionable information by quantifying TILs, determining tumor cell aneuploidy, and quantifying PD-L1 expression on tumor cells in different phases of the cell cycle.
Antitumor immune responses are mediated by CD8+ cytotoxic T lymphocytes (CTLs), and the widespread success of immune checkpoint blockade through PD-1 and CTLA-4 provides clinical evidence that CTLs are capable of effective antitumor activity. 1 TILs have been shown to be key prognostic determinants in a number of solid tumors. [13] [14] [15] Since intratumor TILs are associated with better overall survival, 14 TIL quantification has been included in the panel presented here. Using this approach in the current study, we found decreased CD4+ helper T cells in NSCLC compared with normal lung tissue controls and decreased APCs in tumor compared with normal control lung tissue, suggesting possible mechanisms for impaired immune responses. Although markers of T-cell exhaustion such as LAG 3, TIM-3, and CTLA-4 were not included in the current panel, proliferation as determined by post-G 0 -G 1 percent in the current study served as a powerful marker of T-cell activation and activity. Further probing of the TILs in NSCLC samples revealed that the proliferation of these lymphocytes as measured by the post-G 0 -G 1 percent demonstrated an increase in proliferation in both the CD8+ TILs and the CD4+ TILs (only the increase in CD4+ TILs' proliferation was found to be statistically significant). This contrasts with the decreases in T-helper cells and APCs in terms of contributions to impaired immune response to the tumor. Aneuploidy, which is found in 65% of NSCLC tumors, 18 is a prognostic factor in NSCLC. A meta-analysis concluded that patients with diploid tumors experienced a significant reduction of risk of death from 1 to 5 years. 18 Similarly, in other studies, the 3-year survival rate in patients with aneuploid-type tumors was significantly lower than in those with diploid-type tumors. 19 These studies concluded that the mortality rate in patients with aneuploid tumors was the result of distant metastases, while in patients with diploid tumors, local recurrence was the main reason for death. In the first 3 years after surgical resection, patients with aneuploid tumors were found to be at a higher risk of distant metastases than patients with the diploid type. 19 Here, we have shown that 80% of NSCLCs were aneuploid with DNA indices greater than 1.10. Furthermore, PD-L1 expression was variable from patient to patient depending on where the tumor cells were in the cell cycle. PD-L1 expression in aneuploid tumor cells is particularly important because of the propensity of aneuploidy cells to appear as circulating tumor cells and to eventually metastasize. 20 Finally, it was found that the tumor tissue workflow used in the present study resulted in more actionable information than the currently used IHC method. The processing of the tumor followed very closely well-established processing protocols for lymphoma where new molecular and flow cytometric data are incorporated into the final report for diagnostic and prognostic purposes. 21 At the very minimum, we found that the overall agreement between OncoTect iO and IHC was 95% (Table 2) , with detection of a distinct population of PD-L1-positive cells using OncoTect iO that was missed by IHC (Table 1) . No cases that were positive by IHC were missed by the OncoTect iO Lung Assay. The prognostic information that the OncoTect iO Lung Assay provides on TILs and aneuploidy in addition to PD-L1 expression positions this assay to be used to better inform clinicians about the patient tumor environment and therefore better inform treatment decisions.
